Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM) - correlation with prognostic factors

Cancer/testis (CT) antigens are potential targets for cancer immunotherapy, with NY-ESO-1 being among the most immunogenic. In several clinical trials in malignant melanoma (MM) patients, NY-ESO-1 protein/peptides showed clear evidence of inducing specific immunity. However, little is known about NY...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Velazquez, Elsa F., Jungbluth, Achim A., Yancovitz, Molly, Gnjatic, Sacha, Adams, Sylvia, O'Neill, David, Zavilevich, Kira, Albukh, Tatyana, Christos, Paul, Mazumdar, Madhu, Pavlick, Anna, Polsky, David, Shapiro, Richard, Berman, Russell, Spira, Joanna, Busam, Klaus, Osman, Iman, Bhardwaj, Nina
פורמט: Artigo
שפה:Inglês
יצא לאור: Academy of Cancer Immunology 2007
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2935749/
https://ncbi.nlm.nih.gov/pubmed/17625806
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים